We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




World’s First AI-Powered Tool to Transform Type 1 Diabetes Diagnosis and Treatment

By LabMedica International staff writers
Posted on 09 Jun 2025

For years, testing for Type 1 Diabetes (T1D) has relied on symptoms and biomarkers that typically become evident only at the disease’s onset, making early detection difficult. More...

This is particularly concerning because early-onset T1D, especially before age 10, tends to be more aggressive and is linked to a reduction in life expectancy of up to 16 years. Accurately forecasting disease progression could allow clinicians to act earlier. Now, an artificial intelligence (AI)-powered tool is showing promise in assessing T1D risk and predicting how patients will respond to treatments, potentially reshaping how the disease is identified and managed.

An international research team led by Western Sydney University (Penrith, NSW, Australia) has created a novel risk score based on microRNAs—tiny RNA molecules found in blood—that can effectively track the evolving risk of developing T1D. These same microRNA markers also predicted early responses to treatments such as islet cell transplantation and the drug imatinib. Published in Nature Medicine, the study evaluated molecular data from 5,983 samples collected from participants in Australia, Canada, Denmark, Hong Kong SAR China, India, New Zealand, and the USA. This led to the development of a Dynamic Risk Score (DRS4C) capable of identifying individuals as either having or not having T1D.

Using AI, the team further refined the risk score, which was validated with data from 662 additional participants. Remarkably, just one hour after therapy, the tool could predict which T1D patients would remain insulin-independent. The same microRNA profile also distinguished between responders and non-responders to the T1D drug therapy before treatment even began. Aside from gauging T1D risk and treatment effectiveness, the risk score may also help differentiate between T1D and Type 2 Diabetes (T2D)—a diagnostic challenge, especially in adults. A sub-analysis highlighted the tool’s potential to classify T2D individuals apart from those with T1D, an area the researchers plan to explore further, as many adult-onset T1D cases are often misdiagnosed as T2D.

“Genetic markers identify lifelong risk, it’s like knowing you live in a flood zone, but dynamic risk scores offer a real-time check on the rising water levels; it reflects current risk rather than a lifelong sentence, allowing for timely and adaptive monitoring without stigma,” said lead researcher Dr. Mugdha Joglekar at the Western Sydney University.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Urine Analyzer
respons® UDS100
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.